

ASX Announcement

29 October 2020

Regeneus receives \$5.6M milestone payment from Kyocera

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, is pleased to announce it has received a milestone payment of A\$5.6M from Kyocera Corporation (Kyocera, TYO:6971).

This milestone payment follows Kyocera's receipt of the initial Progenza™ OA data package as part of the collaboration and licence agreement signed 11 August, and the first payment received on 28 August.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com